You might like
Synthekine Joins Quest To Tame IL-2 In Cancer Therapies. First clinical data from Synthekine’s IL-2 candidate and that of rivals Medicenna were presented at the AACR, suggesting there’s life in the modality yet. Related StoriesNovartis... ow.ly/Uguv105pFPy #PharmaScrip
The Breakthrough of the Year @AAAS Bhaumik Prize goes to the 2 scientists who pushed/fought to get GLP-1 drugs to treat obesity (which took decades!) aaas.org/news/innovator… by @MeaganPhelan, with the whole, fascinating story pleased to be a member of the selection committee
Winners | Losers of Biopharma for 2023 A newsroom-wide list with dozens of entries ... and emojis to match Check out our review of the year: endpts.com/biotech-and-ph…
Next month, Truvian will present performance of its blood testing solution from a recent multisite #clinicalstudy at the @_AACC Annual Scientific Meeting. Read more about our poster presentation: bit.ly/3PzqXes
The transition of all the usual suspect biotech companies from covid plays to weight loss plays will be entertaining to watch.
Hi everyone - I am looking for my next career opportunity. I have 20+ years of experience, including a journalism career (Bloomberg, bylines in NYT, SF Chron) + a decade in PR, working at an agency (W2O) and in-house at biopharma (J&J, Audentes, Resilience & Kriya). DMs are open!
Today we announced positive results from our Ph3 EXPLORER-CN trial of mavacamten for the treatment of Chinese patients w/ oHCM. Learn more about the data and the impact access will have for patients in need: bit.ly/41GMxRj #LIAN $LIAN #data
We're collaborating with @Regeneron to discover, develop and commercialize potentially transformative #Treg therapies for people with #ulcerativecolitis, #crohns and other #autoimmune and #inflammatorydiseases. Learn more: bit.ly/40laZao. #IBD
Tomorrow, our CEO, Debanjan Ray, will present at the 41st Annual J.P. Morgan Healthcare Conference at 1:30 p.m. PT to discuss Synthekine’s rapid growth, recent Series C financing, and evolving therapeutic pipeline. Learn more: bit.ly/3CwNX6n #JPM2023
We’re thrilled to announce our $100 million Series C financing, which will be used to advance our pipeline of differentiated cytokine therapeutics. Learn more about the #financing & upcoming #JPM23 presentation: bit.ly/3CwNX6n
My #Spotifywrapped was led by two songs from @JamesGunn playlists that my 5 year old requests daily on the drive to school: “the silly dance song” (Do You Wanna Taste It) from @WigWam_Official and “the baby Groot song” (Mr Blue Sky) from @JeffLynnesELO
Congratulations to client Imago on today's news! Proud to have worked with this incredible team over the past few years as they grew as a company and advanced bomedemstat.
We're excited to announce the acquisition of Redpin Therapeutics and its leading chemogenetics platform. This acquisition marks our expansion into neurology, with a pipeline to address severe diseases such as #epilepsy and #trigeminalneuralgia. Learn more: kriyatherapeutics.com/2022/11/16/kri…
Even though often called 'benign tremor,' the effects of essential tremor have significant impact on patients.
Despite being one of the most common #MovementDisorders, #EssentialTremor is under-recognized & many patients remain untreated. Our claims analysis published in @AdvancesTherapy highlights the complexity of care and extent of disease impact on ET patients: bit.ly/3T8Vdf7
It has been a year of significant growth for @surrozen and its #Wnt focused pipeline, including a new deal announced today with @Boehringer for its lead program in retinal disease
We are proud to announce a new partnership with @Boehringer to research and develop SZN-413 for treatment of retinal diseases. Learn more in today’s press release: bit.ly/3SZaCxV
A fantastic year of growth for this team, and I'm glad to see it recognized with a spot on the #Endpoints11
We're thrilled to be named one of this year's #Endpoints11 and are proud of the progress we've made towards our bold vision of developing transformative therapies for solid tumor cancers. Explore our highlights below & read more: bit.ly/3qZNqUA, bit.ly/3xJqsEC.
We are proud to be chosen as one of this year’s #Fierce15 winners! Thank you, @FierceBiotech, for recognizing the work of our amazing team and our mission to develop the next generation of #cytokine therapeutics. Learn more: bwnews.pr/3DzhGx5 #Fierce152022
This morning, we announced our recent $33M expanded financing, exciting advancements in our diabetes and obesity clinical program and revealed our new name change to #StructureTx! Learn more about our latest milestones and what's to come here: bit.ly/3SiMmXY
Love the excitement from this wonderful team. Congratulations to all at @imagobiorx
We're thrilled to be named one of this year's #Endpoints11 and are proud of the progress we've made towards our bold vision of developing transformative therapies for solid tumor cancers. Explore our highlights below & read more: bit.ly/3qZNqUA, bit.ly/3xJqsEC.
United States Trends
- 1. Paddy N/A
- 2. #UFC324 N/A
- 3. Alex Pretti N/A
- 4. Ilia N/A
- 5. O'Malley N/A
- 6. Derrick Lewis N/A
- 7. Derrick Lewis N/A
- 8. Suga N/A
- 9. #SNME N/A
- 10. WHAT A FIGHT N/A
- 11. Muratalla N/A
- 12. Moro N/A
- 13. #Skyscrapperlive N/A
- 14. #UFCParamount N/A
- 15. Arman N/A
- 16. Silva N/A
- 17. Song Yadong N/A
- 18. Dragon Ball N/A
- 19. Kyle Rittenhouse N/A
- 20. Battle of Gods N/A
Something went wrong.
Something went wrong.